New drug cocktail aims to tame transplant complication
NCT ID NCT07185633
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a combination of Gecacitinib (a pill) and a corticosteroid as the first treatment for grade II to IV acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The study will enroll 25 adults who have recently received a transplant and have not been on steroids for more than 2 days. Participants will take the drugs for at least 28 days, and if they respond well, treatment may continue up to 24 weeks. The main goal is to see how many patients achieve a complete or partial response by day 28.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gecacitinib and methylprednisolone (a corticosteroid)
- What this could lead to
- If successful, this combination could become a new first-line treatment option for acute graft-versus-host disease, improving response rates and reducing the need for additional therapies.
- What could go wrong
- This is a small, early-phase trial with only 25 participants and no comparison group, so results may not be conclusive. There are also risks from the drugs, including infection and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGVHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.